These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 9157592)
1. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Svensson PJ; Zöller B; Dahlbäck B Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592 [TBL] [Abstract][Full Text] [Related]
2. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients. Freyburger G; Javorschi S; Labrouche S; Bernard P Thromb Haemost; 1997 Nov; 78(5):1360-5. PubMed ID: 9408020 [TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance--a major risk factor for thrombosis. Rosén SB; Sturk A Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726 [TBL] [Abstract][Full Text] [Related]
4. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays. Favaloro EJ; Mirochnik O; McDonald D Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912 [TBL] [Abstract][Full Text] [Related]
5. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134 [TBL] [Abstract][Full Text] [Related]
6. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy]. Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280 [TBL] [Abstract][Full Text] [Related]
8. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis. Dahlbck B J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175 [TBL] [Abstract][Full Text] [Related]
9. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty. Svensson PJ; Benoni G; Fredin H; Björgell O; Nilsson P; Hedlund U; Nylander G; Bergqvist D; Dahlbäck B Thromb Haemost; 1997 Sep; 78(3):993-6. PubMed ID: 9308742 [TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis. Gessoni G; Valverde S Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946 [TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Dahlbäck B Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959 [TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma. Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344 [TBL] [Abstract][Full Text] [Related]
13. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Hillarp A; Zöller B; Svensson PJ; Dahlbäck B Thromb Haemost; 1997 Sep; 78(3):990-2. PubMed ID: 9308741 [TBL] [Abstract][Full Text] [Related]
14. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. Svensson PJ; Zöller B; Mattiasson I; Dahlbäck B J Intern Med; 1997 May; 241(5):379-85. PubMed ID: 9183305 [TBL] [Abstract][Full Text] [Related]
15. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients. Montes MA; Fox EA; Longtine JA; Dorfman DM Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899 [TBL] [Abstract][Full Text] [Related]
16. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Dahlbäck B Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201 [TBL] [Abstract][Full Text] [Related]
17. Resistance to activated protein C as a basis for venous thrombosis. Svensson PJ; Dahlbäck B N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317 [TBL] [Abstract][Full Text] [Related]
18. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320 [TBL] [Abstract][Full Text] [Related]
19. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT. Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751 [TBL] [Abstract][Full Text] [Related]
20. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Martinelli I; Cattaneo M; Panzeri D; Mannucci PM Thromb Haemost; 1997 Mar; 77(3):440-3. PubMed ID: 9065990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]